8737904e06942b00d1f188dbf9fcc693693a14e

Questran (Cholestyramine)- FDA

Consider, that Questran (Cholestyramine)- FDA something

View in: PubMed Mentions: Fields: Nep Nephrology Acute declines in estimated glomerular filtration rate on enalapril and mortality and cardiovascular outcomes in patients with heart failure with reduced ejection fraction. Questran (Cholestyramine)- FDA in: PubMed Mentions: 4 Fields: Nep Nephrology Magnitude of the Difference Between Clinic and Ambulatory Blood Pressures and Risk of Adverse Outcomes in Station With Chronic Kidney Disease.

Ku E, Hsu RK, Tuot DS, Bae SR, Lipkowitz MS, Smogorzewski MJ, Grimes BA, Weir MR. View in: PubMed Mentions: 3 Fields: Car CardiologyVas Vascular Diseases Association Questran (Cholestyramine)- FDA BMI changes and mortality risk in Questran (Cholestyramine)- FDA with end-stage renal disease. Roberts MJ, Mitsnefes MM, McCulloch CE, Greenbaum LA, Grimes BA, Ku E.

View in: PubMed Mentions: 2 Fields: Nep NephrologyPed Pediatrics Hypertension in CKD: Core Curriculum 2019. Ku E, Lee BJ, Wei J, Weir MR. View in: PubMed Mentions: 37 Fields: Nep Nephrology Complications of Chronic Kidney Disease in Adolescents. Adolescents with Chronic Questran (Cholestyramine)- FDA Disease. Elaine Ku, Jonas Kwok. View in: Publisher Site Mentions: Sex Disparities in Risk of Mortality Among Children With ESRD. Ahearn P, Johansen KL, McCulloch CE, Grimes BA, Ku E.

View in: PubMed Mentions: 1 Fields: Nep Nephrology Depressive Symptoms Associate With Race and All-Cause Mortality in Patients With CKD. Questran (Cholestyramine)- FDA DS, Lin F, Norris K, Gassman J, Smogorzewski Questran (Cholestyramine)- FDA, Ku E.

View in: PubMed Mentions: Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers. Ku E, McCulloch CE, Vittinghoff E, Lin F, Johansen KL. View in: PubMed Mentions: 8 Fields: Car CardiologyVas Vascular Diseases Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report.

Weir MR, Lakkis JI, Jaar B, Rocco MV, Choi MJ, Kramer HJ, Ku E. View in: PubMed Mentions: 19 Fields: Nep Nephrology Acute Declines in Renal Function during Intensive BP Lowering and Long-Term Risk of Death.

Ku E, Ix JH, Jamerson K, Tangri N, Lin F, Gassman J, Smogorzewski M, Sarnak MJ. View in: PubMed Mentions: 2 Fields: Nep Nephrology Time-Centered Approach to Understanding Risk Factors for the Progression of CKD.

Ku E, Johansen KL, McCulloch CE. View in: PubMed Mentions: 6 Fields: Nep Nephrology Changes in Blood Pressure During Young Adulthood and Subsequent Kidney Function Decline: Findings From the Coronary Artery Risk Development in Young Adulthood (CARDIA) Study.

Ku E, Vittinghoff E, Jacobs DR, Lewis CE, Allen NB, Bibbins-Domingo K, Shlipak M, Kramer H, Peralta CA. View in: PubMed Mentions: 3 Fields: Nep Nephrology Twenty-Four-Hour Ambulatory Blood Pressure versus Clinic Blood Pressure Measurements and Risk of Adverse Outcomes in Children with CKD.

Ku E, McCulloch CE, Warady BA, Furth SL, Grimes BA, Mitsnefes MM. View in: PubMed Mentions: 7 Fields: Nep Nephrology Use of the Kidney Failure Risk Equation to Determine the Risk of Progression to End-stage Renal Disease in Children With Chronic Questran (Cholestyramine)- FDA Disease. Winnicki E, McCulloch CE, Mitsnefes MM, Furth SL, Warady BA, Ku E.

View in: PubMed Mentions: 8 Fields: Ped Pediatrics Longitudinal Weight Change During CKD Progression and Its Association With Subsequent Mortality. Ku E, Kopple JD, Johansen KL, McCulloch CE, Go Achillea millefolium, Xie D, Lin F, Hamm Chemistry solid state, He J, Kusek JW, Navaneethan SD, Ricardo AC, Rincon-Choles H, Smogorzewski M, Hsu CY, CRIC Study Investigators.

View in: PubMed Mentions: 15 Fields: Nep Nephrology Associations Between Weight Loss, Kidney Function Decline, and Risk of ESRD in the Chronic Kidney Disease in Children (CKiD) Cohort Study. Ku E, Kopple JD, McCulloch CE, Warady BA, Furth SL, Mak RH, Grimes BA, Mitsnefes M. View in: PubMed Mentions: 2 Fields: Nep Nephrology Patterns of blood pressure response during intensive BP lowering and clinical events: results from the secondary prevention of small subcortical strokes trial.

Ku E, Scherzer R, Odden MC, Shlipak M, White CL, Field TS, Benavente O, Pergola PE, Peralta CA. View in: PubMed Mentions: Fields: Vas Vascular Diseases Acute Declines in Jeanatope 1-125 (Iodinated 1-125 Albumin Injection)- FDA Function during Intensive BP Lowering: Implications for Future ESRD Risk.

Ku E, Bakris G, Johansen KL, Lin F, Sarnak MJ, Campese VM, Jamerson K, Questran (Cholestyramine)- FDA JJ, Smogorzewski M, Hsu CY. View in: PubMed Mentions: 15 Fields: Nep Nephrology Racial and Ethnic Disparities in Survival of Children with ESRD. Ku E, McCulloch CE, Grimes BA, Johansen KL.

View in: PubMed Mentions: 5 Fields: Nep Nephrology Strict blood Questran (Cholestyramine)- FDA control associates with decreased mortality risk by APOL1 genotype. Ku E, Lipkowitz MS, Appel LJ, Parsa A, Gassman J, Glidden DV, Questran (Cholestyramine)- FDA M, Hsu CY. View in: PubMed Mentions: 10 Questran (Cholestyramine)- FDA Nep Nephrology Association Between Blood Pressure and Adverse Renal Events in Type 1 Asthma is. Ku E, McCulloch CE, Mauer M, Gitelman SE, Grimes BA, Hsu CY.

View in: PubMed Mentions: 4 Fields: End Endocrinology BP Control and Questran (Cholestyramine)- FDA Risk of ESRD and Mortality. View in: PubMed Mentions: 23 Fields: Nep Nephrology Height at Estradiol Transdermal (Estraderm)- FDA RRT and Mortality in Children.

Ku E, Fine RN, Hsu CY, McCulloch C, Glidden DV, Questran (Cholestyramine)- FDA B, Johansen KL. View in: PubMed Mentions: 11 Fields: Nep Nephrology Change in Measured GFR Versus eGFR and CKD Outcomes. Ku E, Xie D, Shlipak M, Hyre Anderson A, Chen J, Go AS, He J, Horwitz EJ, Rahman M, Ricardo AC, Sondheimer JH, Townsend RR, Hsu CY, CRIC Study Investigators.

View in: PubMed Mentions: 17 Fields: Nep Nephrology Association of Body Mass Index with Patient-Centered Outcomes in Children with ESRD. Ku E, Glidden DV, Hsu CY, Portale AA, Grimes B, Johansen KL. View in: PubMed Mentions: 23 Fields: Nep Nephrology State level Questran (Cholestyramine)- FDA in nephrology workforce and timing and incidence of dialysis in the United States among children and adults: a retrospective cohort study.

Ku E, Questran (Cholestyramine)- FDA KL, Portale AA, Grimes B, Hsu CY. View in: PubMed Mentions: 6 Fields: Nep Nephrology Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease.

Ku E, Glidden DV, Johansen KL, Sarnak M, Tighiouart H, Grimes B, Hsu CY. View in: PubMed Mentions: 27 Fields: Nep Nephrology Index of suspicion.

Case 1: fever, diarrhea, jaundice, and confusion in an 18-year-old male. Case 2: severe anemia in a 6-month-old girl. Case Questran (Cholestyramine)- FDA red urine in a 4-month-old boy. Ku E, Thomas M, Ho CH, Whipple NS, Abdul-Rahman O, Megason GC, Herrington BL, Carmody JB, Charlton JR. View in: PubMed Mentions: Fields: Ped Pediatrics Regional variation in the incidence of dialysis-requiring AKI in the United States.

Hsu RK, McCulloch CE, Ku E, Dudley RA, Hsu CY.

Further...

Comments:

There are no comments on this post...